Press Release Oct 21 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This filing is a press release from NATCO Pharma Limited regarding a legal update. The company informs that FMC Corporation and FMC Singapore have appealed against a recent court judgment that allowed NATCO to launch its Chlorantraniliprole products. NATCO expresses confidence in its case and anticipates success in the appeal.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Oct 04 2022
- Press Release Sep 24 2022
- Press Release Sep 19 2022
- Press Release Aug 17 2022
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
Later from NATCO Pharma
- Press Release Nov 09 2022
- Press Release Nov 12 2022
- Press Release Nov 16 2022
- Press Release Dec 05 2022
- Press Release Feb 04 2023
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma